Treatment of B-cell Prolymphocytic Leukemia with Normal TP53
When B-cell prolymphocytic leukemia (B-PLL) presents with normal TP53 — confirmed absence of both TP53 deletion and TP53 mutation — this status is a key determinant of the appropriate treatment approach.
Clinical scenario
This protocol applies to B-cell prolymphocytic leukemia in patients with normal TP53: no TP53 deletion and no TP53 mutation are detected. The TP53 status directly informs which therapeutic strategies are considered appropriate for this patient population.
Treatment Approach — Partial Overview
For B-PLL with normal TP53, the treatment approach centres on a chemo-immunotherapy-based strategy. Further options — including targeted agents and transplant considerations — may apply depending on clinical course.
Full regimen details, sequencing, and options are available in the structured protocol below.
References
DOI: 10.1182/asheducation-2015.1.361
- However, for the 50% of cases with normal TP53, a conventional chemo-immunotherapy approach with FCR or bendamustine and rituximab is reasonable.
- For T-PLL, first-line therapy is with intravenous alemtuzumab and for B-PLL is with combination chemo-immunotherapy for patients with normal TP53 and with alemtuzumab or BCR inhibitors for those with deletions or mutations of TP53.
- In B-PLL, depending on the remission duration after first-line treatment, relapse can be managed with the same or similar chemo-immunotherapy regimens.
- Patients with early relapse or that were associated with high-risk genetics (eg, abnormal TP53) may be considered for treatment with novel BCR inhibitors, such as ibrutinib or idelalisib, or other experimental therapies, preferably within a clinical trial setting.
View source ↗